wow, looks like you have it all figured out except. 1) press every day 2) demand for products 3) good company 4) great growth 5) GEOMET owns and operates the only declared Schedule I chemical agent laboratory in the United States 6) you are smarter then 33% of VSR institutions holders 7) 600 staff worldwide don't do nothing with their PHDs and specialized services 8) Key long-term clients include the U.S. Navy, the U.S. Air Force and the U.S. Army Corps of Engineers don't know why they contract 9) $220 Million in Backlog with a 55 million market cap must be a lie 10) strong balance sheet and Technicals mean nothing 11) products are not real on the upgraded web page 12) a complete line of emergency health related products wont sell in the highest demand panic in years 13) EBOLA somehow will disappear after being around for centuries and the out break will never happen again. LOL 14) bashers know best 15) you are to stupid to play the game of run ups, retrace ,run-up and find a new game changing level. Thank you I get it .
People can not read the press right and understand what's going on. That's like saying the hype around android was only because of the cell phone. Then its in notebooks, laptops, cars, servers, satellites, networks and passing information between all digital devices. **** Breaking down the press- The technology has demonstrated capabilities to express( Gene passing-expression- pass desired information ) proteins that were not commercially feasible to produce using other systems, and unlike technologies dependent on transgenic( delivering external stimuli) cells and organisms (eggs, ovaries, rats, mice ,hamsters, bacteria) , utilizes advanced informatics(the passing desired information) and new synthetic biology techniques for superior clinical product design and delivery. This would be putting disease on plants to get them to produce antibodies to cure its self. Extract the desired (Platibodies) virus fighting antibodies. Human clinical trials of product candidates produced with iBio's technology have been funded by the U.S. Department of Defense and the Bill & Melinda Gates Foundation.
Many may not see the dilemma the company is in. Do they go to several small manufacturers or the biggest players? everybody ? How about their own work with many important diseases. Here are a few to enlighten some to the possibilities as this is a lot more them fluff. The iBioLaunch™ platform retains this improved safety and manufacturing profile demonstrated with subunit vaccines, but unlike competitor technologies, our extremely rapid gene sequence to manufacturing timeline (as little as one month) makes the iBio technology the manufacturing platform of choice when rapid response to pandemic threats is paramount. The iBioLaunch expression platform has been used to manufacture vaccine candidates that represent a broad range of viral, bacterial, and parasitic threats to human health. The technology has been used to successfully produce vaccine components that could not be manufactured using bacterial, yeast, or animal cell expression systems, demonstrating a breadth of application that is unmatched. Each of these vaccines is available to be licensed from iBio along with the iBioLaunch manufacturing platform, providing a turnkey entry into vaccine development and manufacturing. Influenza vaccines — As part of its collaboration with external agencies such as the Bill & Melinda Gates Foundation Global Health Initiative and the US Department of Defense Advanced Research Projects Agency, subunit vaccines for avian influenza (H5N1) and pandemic influenza (H1N1) have been created and advanced into human safety and immunogencity clinical studies. These vaccines consist of the viral hemagglutinin (HA) antigen, which is known to produce a protective immune response in humans. Yellow Fever- In partnership with Fiocruz/Bio-Manguinhos of Brazil, iBio and its research collaborator, the Fraunhofer USA Center for Molecular Biotechnology, have undertaken the development of this next-generation yellow fever vaccine. A license agreement for the iBioLaunch manufacturing platform applied to the yellow fever vaccine has been established with Fiocruz/Bio-Manguinhos and, by mutual agreement, may be expanded to include other product applications. Malaria — Malaria is one of the greatest threats to human health in the world. This vaccine candidate, which has shown great promise in laboratory studies of malaria transmission, was developed in a partnership with the Bill & Melinda Gates Foundation Global Health initiative. Hookworm- iBioLaunch technology is being used to produce a vaccine antigen to an enzyme found in the gut of the hookworm. Antibodies to this gut enzyme block its action, which is normally to break down hemoglobin in the blood as a source of iron for the hookworm. However, commercially useful amounts of the antigen can be manufactured using the iBioLaunch plant expression technology, and development of a vaccine in partnership with the Sabin Vaccine Research Institute is proceeding towards human safety and efficacy studies. Human papilloma virus - iBioLaunch technology has been used to produce an experimental vaccine to one serotype of HPV (HPV-16) which causes the regression and loss of established HPV tumors in an animal model. Such a vaccine in humans has the potential to treat patients with established HPV-related cancers, for which current therapeutic options involve surgical resection followed by chemotherapy and/or radiation treatment. Bacterial pathogens — The iBioLaunch system has been used to produce vaccines against plague (Yersinia pestis) and anthrax (Bacillus anthracis). The plague vaccine consists of two bacterial antigens (F1 and LcrV) and has been demonstrated in primates to provide complete protection against inhaled plague challenges when administered with an adjuvant.
. Our current pipeline includes:
• Monoclonal antibodies
• Interferons & cytokines
• Enzymes for replacement therapy
• Plasma-derived proteins
• Growth factors
• Protease inhibitors
• Clotting factors
Our technology has been validated in multiple vaccine and therapeutic product categories, .
I feel Government will need both animal and plant serums. Brantly and Writebol used it and it It works. To save time I feel they will go the IBIO route first. They could be First in the door, and if successful, the rest will be history. The contract is not signed and ( hopefully) it will be huge win with a major manufacturer. The contract could be for Ebola or many tests on many diseases. It may be for the three manufactures that already deal with Plantibodies or a complete buy out from a AMGEN. Anyway, RJ Reynalds (Nicotiana benthamiana tabacco) ,IBIO ( platform,technology) and Caliber Biotherapeutics LLC (maker) are in the Collaboration Agreement. I feel our licensing will be to many manufacturers, drug makers, and many virus studies with royalties. Then we have a (BIG) platform and standard way to convert Animal techniques to plants with special qualities, cost savings, tolerability's, no plant animal transfers, homogeneity, live , yield optimization ,speed, efficiency, standardized procedures. The Gates Foundation, for one, is working with iBio, one of the few publicly traded “plantibody” companies, to make low-cost vaccines for developing . The PPS has some foreword looking possibilities as to other GOODWILL, intangible assessments. This would only be normal to look at the situation as a standard code or platform on the computer. You build the code and platform and the applications, games, uses develop in different areas in this case diseases.
Real good questions. I have spent a couple days searching this company and a couple weeks on the groups. The platform is not only for EBOLA. It is a technique and science that can duplicate, clone, make the same, faster and a bigger quantity. Let me highlight the patent and couple of press releases. DONT only make the mistake of thinking the platform is only for EBOLA but other types of bacteria, diseases and viruses. What forces a plant to produces antibodies (plantbodies) and reactions to foreign materials injected. 1) iBio said the "superior homogeneity of antibody glysolylation," or the addition of sugars to proteins, in plants could have significant efficacy advantages compared to similar antibodies produced in Chinese hamster ovary (CHO) cells. ( "superior homogeneity ) or make the same . 2) Chinese hamster ovary (CHO) , chicken, mice, eggs, ovaries, insect cells are the animal methods the platform is replacing with plants for the reaction and antibodies. 3) The USAMRIID, Mapp, and KBP team published work in 2012 demonstrating the the three antibodies produced in Nicotiana benthamiana were superior to those made in Chinese hamster ovary (CHO) cells, the most common FDA-approved host for human therapeutics -- once established the plant method can be adopted for other viruses, bacteria's, diseases. the door is opened. 4) Nicotiana benthamiana has many important anti viral qualities and used in other studies. 5) Many companies might manufacture-That is a good point that many companies can use the package (/license/royalties) , the platform , and technologies. patents- clonal expression - the process by which information from a gene is used in biochemistry from same cell/gene/ancestry - reproduce same qualities. The patent (European patent EP 1664322) covers iBio’s carrier molecule fusion protein technology (iBioModulatorTM) for therapeutic proteins and vaccines. (serial no:05723389.2) entitled "Systems and Methods for Clonal Expression in Plants, - IMPORTANCE Clonal –Clone make the same or alike- Gene expression- pass desired information , self-replicating the process by which information from a gene is used in biochemistry. Research to identify molecules with potential for preventative and therapeutic use (antibodies, enzymes, hormones and vaccine antigens) is of paramount importance to health and medicine. Historically, many of these molecules were recovered from human or animal sources. However, low quantities of target product in the source material coupled with immense costs, and more importantly, safety, have limited the availability of therapeutics and vaccines for prevention and treatment of many diseases around the world.
Sentiment: Strong Buy
iBio uses the iBioLaunch platform, which is a proprietary gene expression technology capable of producing high levels of target proteins in plants. Ultimately these proteins are used to create vaccines and can be produced quickly and efficiently. Using this technology iBio can bring its Ebola treatment to market quicker than expected.
• IBIO comes to market faster, cheaper, and given to Dr. Kent Brantly and Nancy Writebol (ZMapp) and changing to animal antibodies will take time and have to start over
• Ibio, working with Fraunhofer Center for Molecular Biotechnology, developed a plant-based technology called IBIO that can bring vaccines to market more rapidly.
• The government is in advanced discussions with Caliber Biotherapeutics on the initiative. Caliber can produce ZMapp in large quantities utilizing its plant-based capabilities and Ibos’ iBioLaunch technology which Caliber licensed last year. iBioLaunch causes green plants to produce commercial quantities of targeted human proteins in proper form for use in pharmaceuticals.
• The Company confirmed in a statement that it has the means to quickly manufacture mass quantities of treatments for Ebola in conjunction with privately held Caliber Biotherapeutics LLC. Federal officials said some of the early doses of ZMapp will be tested for safety in healthy volunteers. The Wellcome Trust has given a grant of about $5.2 million to a consortium that will move quickly to test ZMapp and other drugs in sick patients in Africa.
• The Gates Foundation, for one, is working with iBio, one of the few publicly traded “plantibody” companies, to make low-cost vaccines for developing countries. A federal official said, speaking on condition of anonymity because contracts have not yet been signed. “Caliber is certainly one we’re considering.” Andrew Pollack,
• Under the terms of the license agreement, Ibio will receive license and milestone fees based on the development of product targets selected by Caliber.
cut and search ........ Readers should also take with a grain of salt the press reports that the cocktail has saved Dr. Brantly, reversed his breathing problems, or cleared his rash.
but look at other reports coming out about curing breathing problems and rashes............ This is only the tip of the ICE BURG !!!!!!!! Yellow fevor HIV , influenza all viruses will be studies and passing the first safety first stage keep up rashes breathing problems and a host of others. CUT and search yourself ! .......................The USAMRIID, Mapp, and KBP team published work in 2012 demonstrating the the three antibodies produced in Nicotiana benthamiana were superior to those made in Chinese hamster ovary (CHO) cells, the most common FDA-approved host for human therapeutics that certain sugar molecules for biological activity.
they are testing the plant based, Tabaco , serum now. a. big head start... Amgen must start it all over using animal techniques and testing. Lets see if IBIO holds out for a good contract and royalties. This will jump start their platform to become the technique of choice over chicken cells, eggs, ovaries OR NLNK cow method. TKMR could even want to produce their drug faster with proven techniques. USING TABACCO is not new, What's new is developing it fast and consistent , this is where IBIO could shine. .
Sorry we had the retracement the 15th down to 1.5 from 2.5. That run from 75 cents to 2.5 was nice. We may run into trouble about 5and 6 and get a fib retrace to 4 ............ I am expecting news within a week on different manufacturers settling/contracts and licensing with royalties. Lets see how far that 50 million from the Gates Foundation goes. In two or three weeks I expect some early news on testing. After that the Platform will be used by many different manufacturers of different diseases.
there are many differences between the treatment the two Americans got at an Atlanta hospital, and in west Africa, where even such basics as sterile fluids can be in short supply. the dose will have to be standardized and attention after. The drug is being tested and I am betting on a winner.
It also probably helped that the two Americans were considered healthy and well nourished before they were infected and received prompt care, experts say. Before this is over the platform and the Plant approach will be used more.
THATS BS .............They know ZMapp works if they follow the same exact science used to treat Dr. Kent Brantly and Nancy Writebol, American medical missionaries in Liberia, had contracted the deadly Ebola virus, ZMapp, the experimental anti-Ebola drug developed by Mapp Biopharmaceutical and used to treat Brantly and Writebol. It works. iBio said the "superior homogeneity of antibody glysolylation," or the addition of sugars to proteins, in plants could have significant efficacy advantages compared to similar antibodies produced in Chinese hamster ovary (CHO) cells. The Wellcome Trust has given a grant of about $5.2 million to a consortium that will move quickly to test ZMapp and other drugs in sick patients in Africa. “We’re going with multiple manufacturers,” a federal official said, speaking on condition of anonymity because contracts have not yet been signed. “Caliber is certainly one we’re considering.” Andrew Pollack, PLEASE cut and paste this in a search for clarification. It is past speculation and leaning toward IBIO!!!!!!!!!!
Do you have knowledge to back your hypothesis or no knowledge of ZMapp talking to IBIO and Caliber Biotherapeutics............ My money is here because I very much feel, they need other manufacturing facilities to duplicate the very same process that Caliber Biotherapeutics did. To start over will take time and they want to standardize the different facilities. LIKE KERRY said "all hands on DECK".
You don't know #$%$ if you cant explain the last patents and why they want IBIO. This is a 5 dollar stock easy with the method to reproduce most of the traditional chick (animal) manufacturing technics. If this next two weeks pans out you will be the last to understand. Can you please tell me why cloning, infecting and extracting antibodies that are exactly the same isn't important? Then there is the platform that is over you head reproducing animal methods. GREEN is IN!
DAVID the best part is they must use Caliber and do the EXACT method and manufacturing machines, materials and way caliber did it or start from scratch. The only way they can duplicate the cloning ,infecting, retrieval, precision and making the drug ........... They cant pass chicken ovaries off as plant based. If they want what has passed in the past with the DRs.
I would start by reading and understand the last patents and What IBIO did for ZMapp. Cloning? Platform? do you understand infecting the Tabaco and doing it over and over the same with precision. I don't want to hear your lies until you do your home work. Don't give me the shares out and cashing in. They are known and recorded Shares Outstanding5: 67.46M
Float: 55.86M and a 216 market cap.
confirmation on the new patents cloning and making quantities with plants. Making them faster and the same time and time again. Before I bash I would look at what is happening. The platform replicates old methods and the manufacturers must follow IBIOs lead and manufacturing to the T or start over. $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
SHORT SCAM alert. Many shorts are looking at this going up 100%............... This is the platform being OKed for other viruses. The Animal cells and eggs can be replaced by Tabaco plants -faster , cheaper and better quantities. YOU are looking at the beginning of the revolution going through IBIO. YOU have no clue about their new cloning patents and Patents making it easier to duplicate the traditional chicken ovary methods............ COVER fools this is it!!!!!!!!!!!!!!!!!!!!!!!!!!! confirmation complete.
learn to read the odds and grow a pair, It looks very good. The press, history and technology looks good. Kerry just said all HANDS ON DECK treating this.
iBioLaunch™ platform patents and related proprietary technology to further development and production of antibodies that target the Ebola virus, and (ii) that iBio has an ongoing relationship with Caliber Biotherapeutics LLC reflected by a License and Collaboration Agreement dated February 14, 2013 pursuant to which iBio and Caliber have been collaborating on commercial opportunities for recombinant antibodies and antibody-related proteins based on the speed, efficiency, and cost advantages of producing pharmaceutical proteins in plants instead of with bioreactor-based manufacturing methods. The Biomedical Advanced Research and Development Authority, a branch of the Department of Health and Human Services, is considering additional production from Caliber, which is based in Bryan, Texas, about 175 miles south of Dallas . The company can produce the drug in millions of tobacco plants, according to federal officials and pharmaceutical industry executives. The Company confirmed in a statement that it has the means to quickly manufacture mass quantities of treatments for Ebola in conjunction with privately held Caliber Biotherapeutics LLC.
The resources are not there for any single or multiple private organizations at this point. Dr. Ron Waldman. We know what needs to be doon but it is not happening fast enough. The Gates Foundation, for one, is working with iBio, one of the few publicly traded “plantibody” companies, to make low-cost vaccines for developing countries. Federal officials said some of the early doses of ZMapp will be tested for safety in healthy volunteers. The Wellcome Trust has given a grant of about $5.2 million to a consortium that will move quickly to test ZMapp and other drugs in sick patients in Africa. “We’re going with multiple manufacturers,” a federal official said, speaking on condition of anonymity because contracts have not yet been signed. “Caliber is certainly one we’re considering.” Andrew Pollack,